Unlabelled: There is a meta-analysis of clinical trials results concerning the evaluation of efficiency of the drug Proteflazid® (drops) in the treatment of adult patients with herpesvirus and mixed infections.
Aim: Objective of the study: to evaluate the clinical efficacy of the drug Proteflazid® in a treatment of herpesvirus (HSV-1, HSV-2) and mixed infections in adults by meta-analysis of clinical trials.
Materials And Methods: In meta-analysis, 16 scientific sources with results of controlled studies with participation of 1336 patients over 18 y.o. during 2003-2015 are included.
Results: Obtained data are indicative of efficiency of the drug Proteflazid® in the treatment of patients with herpesvirus and mixed infections. Proteflazid® induces improvement in the main clinical signs of diseases, promotes elimination of herpesviruses from organism and prevention of relapses.
Conclusions: Proteflazid® in the therapy of various clinical forms of HHVs infection promotes the improvement in the main clinical signs of diseases, elimination of HSV-1 and HSV-2; prevention of relapses of diseases (ophthalmoherpes, genital herpes) after completion of the treatment. Therapy of mixed infections (HSV, bacteria, protozoa, fungi) using the drug Proteflazid® promotes improvement in the main clinical signs of diseases, improvement in vaginal mircoflora condition and improvement in local changes in the cervix in women with inflammatory diseases of genital organs as well as in prevention of relapses of genital inflammatory diseases and chronic pyelonephritis.
Download full-text PDF |
Source |
|---|
Publication Analysis
Top Keywords
Similar Publications
Background: Current guidelines recommend empiric antibiotic therapy for patients who require hospitalization for community-acquired pneumonia (CAP). We sought to determine whether clinical, imaging or laboratory features in patients hospitalized for CAP in whom PCR is positive for a respiratory virus enable exclusion of bacterial coinfection so that antibiotics can be withheld.
Methods: For this prospective study, we selected patients in whom an etiologic diagnosis was likely to be reached, namely those who provided a high-quality sputum sample at or shortly after admission, and in whom PCR was done to test for a respiratory virus.
Real-world experience with nucleos(t)ide analogue therapy and patient survival rates in chronic viral hepatitis B treatment centers in Eritrea.
Sci Rep
January 2025
Division of National Control of Communicable Diseases, Ministry of Health, Asmara, Eritrea.
Real-world data on treatment outcomes or the quality of large-scale chronic hepatitis B (CHB) treatment programs in sub-Saharan Africa (SSA) is extremely difficult to obtain. In this study, we aimed to provide data on the prevalence and incidence of mortality, loss to follow-up (LFTU), and their associated factors in patients with CHB in three treatment centres in Eritrea. Additional information includes baseline clinical profiles of CHB patients initiated on nucleos(t)ide analogue (NUCs) along with a comparison of treatment with Tenofovir disoproxil fumarate (TDF) vs.
View Article and Find Full Text PDFNeglected class A carbapenemases: Systematic review of IMI/NmcA and FRI from a One Health perspective.
Sci Total Environ
January 2025
Laboratoire de Bactériologie, Centre Hospitalier Universitaire de Montpellier, Montpellier, France; UMR MIVEGEC, Université de Montpellier, IRD, CNRS, Montpellier, France.
Carbapenemase-producing Enterobacterales are pathogens classified as a critical priority by the World Health Organization and a burden on human health worldwide. IMI, NmcA, and FRI are under-detected class A carbapenemases that have been reported in the human, animal and environmental compartments, particularly these last 5 years. Bacteria producing these carbapenemases have been mostly identified in digestive carriage screenings, but they are also involved in severe infections, such as bacteremia.
View Article and Find Full Text PDFPrevalence of intestinal parasites and Helicobacter pylori co-infection in people with gastrointestinal symptoms in Africa: a systematic review and meta-analysis.
BMC Infect Dis
January 2025
Department of Medical Parasitology, School of Biomedical and Laboratory Sciences, College of Medicine and Health Sciences, University of Gondar, Gondar, Ethiopia.
Background: Gastrointestinal infections caused by intestinal parasites and Helicobacter pylori are significant public health issues in Africa, where poor sanitation and limited access to healthcare contribute to high disease burden. Since there was no previous pooled data regarding the intestinal parasites and Helicobacter pylori co-infections among gastrointestinal symptomatic patients in the African context, this review aimed to determine the overall prevalence of intestinal parasites and Helicobacter pylori co-infection in people with gastrointestinal symptoms in Africa.
Methods: The current review followed the Preferred Reporting Items for Systematic Reviews and Meta-analyses (PRISMA) standards and registered in the International Prospective Register of Systematic Reviews (PROSPERO; CRD42024598993).
Epidemiological and clinical characteristics of hospitalized pediatric patients with Mycoplasma pneumoniae pneumonia before and after the COVID-19 pandemic in China: a retrospective multicenter study.
BMC Infect Dis
January 2025
Department of Emergency Medicine, Affiliated Hospital of Jiangsu University, Zhenjiang, Jiangsu, 212001, China.
Background: In China many respiratory pathogens stayed low activities amid the COVID-19 pandemic due to strict measures and controls. We here aimed to study the epidemiological and clinical characteristics of pediatric inpatients with Mycoplasma pneumoniae pneumonia (MPP) after the mandatory COVID-19 restrictions were lifted, in comparison to those before the COVID-19 pandemic.
Methods: We here included 4,296 pediatric patients with MPP, hospitalized by two medical centers in Jiangsu Province, China, from January 2015 to March 2024.
Want AI Summaries of new PubMed Abstracts delivered to your In-box?
Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!